ENDOFERON INSTRUCTIONS

Contains: each medicine contains: active substance proendoferin – 0.3mg, additional substance: sodium chloride – 9mg.

Proendoferin includes the complex of proteins derived from follicles of animal origin.

Contains:protein-stabilizer – bovine serum albumin, near 66kDA; biologically active proteins of the TGF-B family, c.M.m near 56 kDa.

Description: amorphous powder or dry porous mass of the white color.

The course of treatment consists of 3 cycles, each cycle comprises 10 injections of the Endoferin during 3 consecutive months. During the first cycle Endoferin is injected intramuscularly once a day at 0,3mg daily for 10 consecutive days starting from the 5th day of the menstrual cycle. Analogical 10-day courses of injections are administered in the following 2nd and 3d months of menstrual cycles. After clinical studies, it is possible to carry out another 3-month course

1. Open the top of the lid of the medicine container
2. Fill the syringe with 1-1,5 ml of sterile water for injection and inject the sterile water contents into the medicine bottle. Remove the syringe with the needle.
3. Shake the contents of the medicine bottle till it is fully dissolved.
4. Place the medicine bottle into the holding tray located in the package for reheating the medicine.
5. 5. Place the holding tray with medicine bottle into the water heated to 90C to 100C with the lid of the medicine bottle facing up. The time of the heating exposure should be strictly 3 minutes.
6. 6. Remove the medicine bottle from the boiling water and store it in the room temperature for 40 minutes. Fill the syringe with the prepared medicine and inject it intramuscular not later than 40 minutes after reheating.
7. DO not inject the medicine if not reheated.

Experimental data and clinical research results demonstrated that Endoferin has inhibitory effect on misplaced endometrial tissue causing its inactivation and atrophy. Reduces pain syndrome and hyperpolymenorrhea, causes regressive changes of endometrial lesions. During animal testing there was shown significant suppression of the production of the proinflammatory cytokines – interferon-y and a-factor tumor necrosis. During 3-month parenteral administration in animals in dosages, exceeding therapeutic ones, Endoferin does not reveal toxic features, does not affect functional state and hysto-morphological structure of inner organs and central nervous system. Endoferin does not disrupt reproductive function, does not cause allergenic, irritating, and mutagenic effect.

Adenomyosis, Endometriosis, Infertility

pregnancy.

lactation period.

hypersensitivity to the medicine components.

age before 18 years old.

Endoferin is not a contraceptive, does not block ovulation and does not affect menstrual cycle. Women of childbearing age must use barrier methods of contraception during treatment. For the most effective results you must follow the given scheme of treatment. Endoferin can be used by patients of reproductive age with all forms of endometriosis as an alternative for hormone therapy (progesterones, combined oral contraceptive measures, antigonadotropin and gonadotropin releasing hormone agonist (GnRH-a) therapy). Patients of after reproductive age may use Endoferin as an alternative for surgical treatment with displayed diffuse and diffuse-nodal forms of endometriosis of uterus (including the combination of uterine myoma knots without apathetic blood flow). There is no evidence for oncogene potential as a carcinogenic activity was not studied. Immunogen potential of this medicine is not fully studied, hence patients with often allergic reactions must follow caution. Do not inject Endoferin if not heated.

The combination of Endoferin with other traditional hormonal medicine is not advisable. Do not combine Endoferin with immune stimulators at the same time.

Endoferin is contraindicated during breastfeeding due to insufficient knowledge of its action, during pregnancy due to its possible negative impact on fetal development. At the same time, Endoferin does not have a negative effect on fertility (the possibility of conception).

From Gastrointestinal Tract side – possible appearance of bitter metallic aftertaste after the injection administration. From the cardiovascular side – not discovered. From Central Nervous System side – possible increase of libido. From the side of the blood system – in rare cases – development of leucopenia that does not require additional specific therapy because the normalization of the cellular blood composition happens randomly. From the side of coverlet - not discovered.

There is no information available. Cases of overdose were not observed.

The medicine container by 0,3 mg with the capacity of 5mg, packed up with rubber corks and rolled in aluminum, aluminum-plastis or combined material caps. Each cardboard packet contains of 2 contoured cellular packages with 5 medicine containers, including the instruction for use of the medicinal preparation and holding tray for the medicine container.

between +2 °to +8 °

2 years.

LLC "Region-plus", Belarus
Minsk, Frunze str., 5, room 111
Tel.: +375 (17) 392-32-57
Fax: +375 (17) 392-32-57
E-mail: info@endoferin.ru

RUE "Belmedpreparaty" is the largest pharmaceutical company, the founder of the pharmaceutical industry in Belarus.
Address: 220007, Republic of Belarus,
Minsk, Fabricius str., 30